Lysogene Past Earnings Performance
Past criteria checks 0/6
Lysogene has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 31.4% per year.
Key information
12.5%
Earnings growth rate
25.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 31.4% |
| Return on equity | n/a |
| Net Margin | -195.8% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Lysogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 7 | -14 | 5 | 16 |
| 30 Sep 21 | 9 | -12 | 5 | 16 |
| 30 Jun 21 | 10 | -11 | 5 | 16 |
| 31 Mar 21 | 13 | -8 | 5 | 16 |
| 31 Dec 20 | 16 | -5 | 5 | 16 |
| 30 Sep 20 | 18 | -4 | 5 | 16 |
| 30 Jun 20 | 19 | -2 | 5 | 17 |
| 31 Mar 20 | 18 | -3 | 5 | 17 |
| 31 Dec 19 | 17 | -4 | 4 | 18 |
| 30 Sep 19 | 15 | -5 | 5 | 15 |
| 30 Jun 19 | 13 | -6 | 6 | 13 |
| 31 Mar 19 | 9 | -8 | 6 | 12 |
| 31 Dec 18 | 6 | -11 | 6 | 11 |
| 30 Sep 18 | 4 | -14 | 5 | 13 |
| 30 Jun 18 | 3 | -17 | 4 | 15 |
| 31 Mar 18 | 3 | -17 | 4 | 15 |
| 31 Dec 17 | 3 | -18 | 5 | 15 |
| 30 Sep 17 | 2 | -15 | 4 | 13 |
| 30 Jun 17 | 2 | -13 | 4 | 11 |
| 31 Mar 17 | 2 | -10 | 3 | 8 |
| 31 Dec 16 | 1 | -7 | 2 | 6 |
| 30 Sep 16 | 1 | -6 | 2 | 5 |
| 30 Jun 16 | 1 | -5 | 2 | 4 |
| 31 Mar 16 | 1 | -5 | 2 | 4 |
| 31 Dec 15 | 0 | -4 | 1 | 3 |
Quality Earnings: LYSP is currently unprofitable.
Growing Profit Margin: LYSP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LYSP is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare LYSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYSP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: LYSP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.